Rowan Dartington
2610 The Quadrant, Aztec West, Bristol, BS32 4AQ, United Kingdom
Overview
Rowan Dartington is an online stock brokering and wealth management service. We take wealth management personally. We know that every client is different and every investment decision is personal. We know that by looking at the big picture and the small individual details when managing wealth, we are better placed to help our clients achieve their goals and ambitions, both today and tomorrow. In 1990, we started with a simple idea: to create and preserve wealth by deeply understanding and aligning to the personal values, goals and ambitions of our clients. Today, as one of the leading providers of personalised investment management, our expertise reaches around the world. Crucially, we’re able to translate this truly global view into something really personal, never losing sight of the unique needs of every individual client. As you’d expect from a multi-award winning business, we have a successful track record of consistent investment returns, leading expertise and a personalised customer experience, driven by a team committed to providing the highest possible standard of client service.
- Total investments
- 1
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 0
Sector focus
- Finance
Investment portfolio
- Lab21
Participated · Equity · Jan 2009
Lab21 develops and manufactures molecular and immunodiagnostic products and provides clinical laboratory services for personalised medicine, blood bank screening and other clinical diagnostics. The company operates two divisions: a Clinical Laboratories division that develops molecular diagnostic services and companion diagnostics for oncology and infectious diseases, and a Products division that manufactures infectious disease tests such as malaria, Chagas, syphilis and cytomegalovirus (CMV) for blood screening. Lab21's customers include major pharmaceutical companies, diagnostic manufacturers, clinical laboratories and biotechnology firms. The company has corporate offices in Cambridge, UK and Greenville, South Carolina, and manufacturing/GMP capacity in Cambridge with additional facilities in Newmarket, Camberley and Bridport. Lab21 follows a buy-and-build strategy, is a rapidly growing molecular and immunodiagnostics manufacturer, and was expected to deliver greater than 30% revenue growth in 2012. The company plans to expand GMP manufacturing capability and to grow its international sales channel, particularly into the U.S. Lab21 provides state-of-the-art diagnostic products and services, supporting drug discovery and healthcare, with its clinical reference laboratory and corporate office in Cambridge, UK. Its growing test portfolio offers companion diagnostics and high-technology assays in infectious diseases, oncology and pharmacogenetics, with emerging interests in cardiovascular and metabolic disease. The company announced it has closed a £2.2m round of financing from international private equity investors. New investors Nexus Medical Partners and Rowan Dartington join existing shareholders Merlin Biosciences and Kreos Capital, and Dr Ed Snape of Nexus will join Lab21's board. Lab21 said the funds will be used to progress an acquisition plan and to establish US operations in South Carolina to expand its presence in the North American market. The company expects to complete two European company acquisitions during the first half of next year.
Team
No current team members are available.